2017

Who we work with
The European Medicines Agency (EMA) engages with a wide range of EU patient, consumer and healthcare professional (HCP) organisations all along the medicines lifecycle.

These stakeholder groups bring along their real-life perspective, experience, knowledge and expertise to regulatory decisions.

Collaboration supports transparency and trust in regulatory processes.

Highlights of 2017
- First Public Hearing held at EMA
- Framework for collaboration with academia — adopted
- Agency adopts Principles for Involvement of Young People in its activities
- Personalised Medicines workshop report
- Information session on antimicrobial resistance
- Outcome report on patients in benefit/risk discussions at CHMP meetings

Number of activities and type of representation

<table>
<thead>
<tr>
<th>Type of representation</th>
<th>Number of activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Representing community</td>
<td>400</td>
</tr>
<tr>
<td>Representing own org.</td>
<td>508</td>
</tr>
<tr>
<td>As individuals</td>
<td>346</td>
</tr>
</tbody>
</table>

Patients and HCPs input into benefit-risk assessments*

- Scientific Advice meetings*:
  - Patients: 131
  - HCPs: 40

- Scientific Advisory Groups:
  - Patients: 46
  - HCPs: 48

- Committee consultations:
  - Patients: 104
  - HCPs: 48

*Only showing patient figures for Scientific Advice meetings

Participation in workshops

- Patients participated in workshops as speakers and chairs, and audience members: 138
- HCPs participated in workshops as speakers and chairs, and audience members: 83

Other activities
- Ongoing engagement with general practitioners/family doctors
- EMA action plan related to EC recommendations on product information
- Training and resources for patients
- HCPWP/PCWP joint work plans for 2018-2019

Training and resources

- Video
- Downloads
- Contact
- Twitter
- RSS feed